Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by YI-LONG WU
Phase I Study of the Pan-Pi3k Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors
Anticancer Research
Medicine
Cancer Research
Oncology
Related publications
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Study of NLG919 for Adult Patients With Recurrent Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase 1 Study of Alpelisib (BYL719), an Α- Specific PI3K Inhibitor, in Japanese Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors
Molecular Cancer Therapeutics
Cancer Research
Oncology
